FindTrial
Sign In

A study comparing two laser-based treatments using fat-derived and platelet-rich components for stretch mark improvement

Efficacy and safety of er: yag laser with stromal vascular fraction versus its combination with platelet-rich plasma and normal saline for striae distensae: a comparative study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097188
Enrollment
20
Registered
2025-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L906- Striae atrophicae

Interventions

Intervention1: Er:YAG + Stromal Vascular Fraction: Er:YAG laser (2940 nm, MSP mode
energy 100–200 J/cm², density 5–10%, frequency 30–50 Hz) followed by intradermal SVF injection (0.1–0.2 mL/cm) prepared from autologous adipose tissue as per protocol. Intervention2: Er:YAG + Platelet
energy 100–200 J/cm², density 5–10%, frequency 30–50 Hz) followed by intradermal normal saline (placebo) injections

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a clinical diagnosis of SD who have been stable for more than a year. Both female and male patients aged more than 18 to 70 years with SD over the abdomen. Patients with Fitzpatrick skin type III-V.

Exclusion criteria

Exclusion criteria: Refraining from signing the informed consent form. Patients with a history of keloid formation and collagen vascular diseases. Presence of skin diseases at the treatment site such as infections. Pregnant and lactating patients. Patients with a history of usage of immunosuppressive and retinoid group of drugs. Patients with a previous history of any topical procedures, including injecting filler, dermabrasion, and laser skin resurfacing in the striae site within the last one year.

Design outcomes

Primary

MeasureTime frame
Change in striae volume (objective volumetric improvement) measured by ANTERA™ 3D imaging from baseline to 3 months after the final treatment sessionTimepoint: After 3 months—

Secondary

MeasureTime frame
Changes in skin pigmentation, erythema, texture and color (Antera 3D), and hydration (corneometry) from baseline to follow-up visits; patient and physician global improvement (GAIS and Subject Satisfaction Likert/SSS) at 3 months post-treatment; and safety—type, frequency and severity of adverse events (eg. PIH, erythema, edema, bruising) recorded throughout follow-upTimepoint: After 3 months—

Countries

India

Contacts

Public ContactDr Madura C

CUTIS Academy of Cutaneous Sciences

maduradr@gmail.com9632741998

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026